Smith & Nephew Purchases BlueSky Medical Group

Smith & Nephew (Largo, Fla) announces that its Advanced Wound Management business has agreed to purchase BlueSky Medical Group, Inc. (Carlsbad, Calif).
Negative Pressure Wound Therapy (NPWT) is a technology used to treat chronic wounds, such as diabetic ulcers, pressure sores, and post operative and hard to heal wounds. Because Smith & Nephew does not currently operate in this market segment; the two founders of BlueSky will assist in integrating the business into Smith & Nephew’s Advanced Wound Management business.
Visit http://www.smith-nephew.com or http://www.blueskymedical.com for more information.
 

Swiss-American Skin and Wound Care Program Offers Promising Outcomes

Swiss-American Products, Inc. (Dallas, Tex) has analyzed historical data from the Centers for Medicare and Medicaid Services (CMS) to evaluate long-term care quality measures.
Data proved that pressure ulcer incidence was 17% lower than the national average in facilities that use Swiss-American’s Collective Learning Education And Resources Program (Clear Choice™). The program is designed to help manage patient skin and wound care.
The program is a clinically proven skin and wound care program that offers managed outcomes, education, and a cost-effective fee structure. The program is effective in a variety of patient care facilities and has been used to treat long-term care residents for more than 8 million patient-bed days to date.
Visit http://www.elta.net for more information.
 

KCI Announces Results From Clinical Study

Kinetic Concepts, Inc. (San Antonio, Tex) recently announced the acute phase results of a randomized, controlled, clinical trial (RCT) on the use of the V.A.C^® Therapy in the treatment of complex diabetic foot ulcers where the use of V.A.C. Therapy resulted in various benefits.
Results showed a significant increase in the number of wounds that completely closed, improvement in the overall time to achieve wound closure, and significant improvement in the formation of granulation tissue.
Visit http://www.kci1.com for more information.
 

Greystone Pharmaceuticals and 3M Finalize Distribution Agreement

Greystone Pharmaceuticals, Inc. (Fort Myers, Fla) announces an agreement with 3M Health Care Limited (Loughborough, England) for the supply and distribution of Greystone’s advanced wound care dressing, DerMax^® in the United Kingdom.
Under the agreement, 3M Health Care Limited will brand and distribute the dressing in the United Kingdom, while Greystone’s European wound care products subsidiary, Dermagenics Europe, BV, will manufacture the product for 3M.
The dressing’s intended use is a wound dressing that will manage pressure ulcers (Stages I–IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions. It is the first wound care product able to claim the ability to down regulate the production of certain protein enzymes called matrixmetalloproteinases (MMPs).
Visit http://www.greystonepharmaceuticals.com or http://www.3M.com for more information.